Data di Pubblicazione:
2014
Citazione:
Ataluren treatment of patients with nonsense mutation dystrophinopathy / K. Bushby, R. Finkel, B. Wong, R. Barohn, C. Campbell, G.P. Comi, A.M. Connolly, J.W. Day, K.M. Flanigan, N. Goemans, K.J. Jones, E. Mercuri, R. Quinlivan, J.B. Renfroe, B. Russman, M.M. Ryan, M. Tulinius, T. Voit, S.A. Moore, H. Lee Sweeney, R.T. Abresch, K.L. Coleman, M. Eagle, J. Florence, E. Gappmaier, A.M. Glanzman, E. Henricson, J. Barth, G.L. Elfring, A. Reha, R.J. Spiegel, M.W. O'Donnell, S.W. Peltz, C.M. Mcdonald. - In: MUSCLE & NERVE. - ISSN 0148-639X. - 50:4(2014), pp. 477-487.
Abstract:
Introduction: Dystrophinopathy is a rare, severe muscle disorder, and nonsense mutations are found in 13% of cases. Ataluren was developed to enable ribosomal readthrough of premature stop codons in nonsense mutation (nm) genetic disorders. Methods: Randomized, double-blind, placebo-controlled study; males ≥5 years with nm-dystrophinopathy received study drug orally 3 times daily, ataluren 10, 10, 20 mg/kg (N=57); ataluren 20, 20, 40 mg/kg (N=60); or placebo (N=57) for 48 weeks. The primary endpoint was change in 6-Minute Walk Distance (6MWD) at Week 48. Results: Ataluren was generally well tolerated. The primary endpoint favored ataluren 10, 10, 20 mg/kg versus placebo; the week 48 6MWD Δ=31.3 meters, post hoc P=0.056. Secondary endpoints (timed function tests) showed meaningful differences between ataluren 10, 10, 20 mg/kg, and placebo. Conclusions: As the first investigational new drug targeting the underlying cause of nm-dystrophinopathy, ataluren offers promise as a treatment for this orphan genetic disorder with high unmet medical need.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Duchenne muscular dystrophy; genetic; pediatric; nonsense mutation; orphan
Elenco autori:
K. Bushby, R. Finkel, B. Wong, R. Barohn, C. Campbell, G.P. Comi, A.M. Connolly, J.W. Day, K.M. Flanigan, N. Goemans, K.J. Jones, E. Mercuri, R. Quinlivan, J.B. Renfroe, B. Russman, M.M. Ryan, M. Tulinius, T. Voit, S.A. Moore, H. Lee Sweeney, R.T. Abresch, K.L. Coleman, M. Eagle, J. Florence, E. Gappmaier, A.M. Glanzman, E. Henricson, J. Barth, G.L. Elfring, A. Reha, R.J. Spiegel, M.W. O'Donnell, S.W. Peltz, C.M. Mcdonald
Link alla scheda completa: